MedTrace Logo

Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

NCT01165502 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-01-19

No results posted yet for this study

Summary

The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.

Conditions

  • Healthy

Interventions

DRUG

CM3.1-AC100

MAD study with repeated subcutaneous (sc) doses

DRUG

Placebo

Placebo for compound CM3.1-AC100 s.c.

Sponsors & Collaborators

  • CellMed AG, a subsidiary of BTG plc.

    lead INDUSTRY

Principal Investigators

  • Peter Geigle, Dr. med. · CellMed AG, a subsidiary of BTG plc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165502 on ClinicalTrials.gov